At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Ganirelix acetate +2 moredrug
Likely dose
Ganirelix acetate 25 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sex Hormones and Orthostatic Tolerance
In Brief
A Phase 2 clinical trial evaluating Ganirelix acetate, 17β-Oestradiol, and 1 other intervention for Orthostatic Intolerance. Completed, enrolled 109 participants across 1 site.
Detailed Summary
This study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. Orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOrthostatic Intolerance
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedJun 2010
Primary CompletionDec 2012
Study CompletionMay 2013
TodayJul 2026
First PostedJun 30, 2010
Enrollment StartFeb 1, 2006
Primary CompletionDec 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 16.0 years ago
Interventions
Ganirelix acetatedrug
Ganirelix acetate: .25 ml/day by subcutaneous injection
17β-Oestradioldrug
17 beta estradiol: 0.2 mg/day (patches)
Progesteronedrug
progesterone, 200 mg day-1 oral